Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that localized administration of heat or certain stress protein inducers effectively prevented chemotherapy-induced hair loss in rodent models without affecting chemotherapy efficacy.

This research found that inhibiting HSP90 in a murine model increased cellular plasticity, suggesting a potential role for HSP90 in cancer progression through enhanced adaptability to stress.

This article discusses Kennedy's disease, detailing its genetic cause, symptoms, and diagnostic criteria, but reports no new clinical findings and highlights a lack of causal therapy.

This study found that human scalp hair follicles transplanted onto chemotherapy-treated immunodeficient mice closely mimic chemotherapy-induced hair loss seen in cancer patients, providing a valuable model for research.

This article reviews the multifunctional roles of calreticulin outside the ER and highlights its impact on wound healing in animal models, but reports no new clinical results.

This review discusses the rationale for targeting 5α-reductase isoenzymes in prostate cancer prevention and treatment, highlighting the potential benefits of using inhibitors like dutasteride and finasteride but reports no new experimental results.

This study found that securinine and ajmaline significantly inhibited hepatocellular carcinoma cell viability and induced apoptosis, with securinine showing lower toxicity to normal liver cells.

This study found that the interaction between heat shock protein 90 and lamin A/C is crucial for the growth, migration, and self-aggregation of dermal papilla cells, suggesting a potential role in alopecia areata mechanisms.

In this study, using a novel topical androgen receptor suppressor, fluridil, significantly increased the percentage of growing hairs in males with androgenetic alopecia without systemic absorption or adverse side effects.

Targeted therapies for lung cancer are effective but require careful management of side effects to benefit patients.

This study found that ALRN-6924 effectively protected human hair follicles from cyclophosphamide-induced damage in an ex vivo setting, suggesting it may reduce both acute and permanent chemotherapy-induced alopecia.

This study found that doxorubicin induces hair follicle apoptosis through TRAIL receptor signaling, providing insights for managing chemotherapy-induced hair loss.

In this study, copper-doxorubicin liposomes with multidose therapy reduced systemic toxicity compared to ammonium sulfate-loaded doxorubicin liposomes, while combinatorial strategies further enhanced tumor regression and accumulation.

This study found that folic acid-conjugated magnetic nanoparticles loaded with doxorubicin significantly reduced cell proliferation in HeLa cells, although they were not effective against doxorubicin-resistant HeLa cells.

This study found that Cepharanthine may mitigate doxorubicin-induced senescence by reducing SA-β-Gal activity and restoring autophagy in cell models, offering insights for antiaging drug development.

Mitoxantrone is effective for treating acute leukemia, especially in older patients, with a lower risk of heart damage.

In this study, a 68-year-old man with muscle-invasive bladder cancer and renal insufficiency achieved a partial radiological response to neoadjuvant therapy with gemcitabine and Disitamab Vedotin, without significant adverse events, highlighting a potential alternative for cisplatin-ineligible patients.

This study found that MK-5108 is well tolerated at high doses as monotherapy in cancer patients, showing stable disease and some antitumor activity, particularly in combination with docetaxel.

In this case study, a neoadjuvant therapy combining gemcitabine and Disitamab Vedotin proved effective and safe for a muscle-invasive bladder cancer patient with severe renal insufficiency, who could not tolerate platinum-based treatments. The study suggests this regimen may be a viable alternative, pending further research.

This study found that the DOX derivative AD198 more effectively inhibited cell viability and induced apoptosis in canine cancer cell lines K9TCC and K9OSA compared to DOX in vitro.

This study found that glibenclamide exhibited a cytostatic effect on MDA-MB-231 breast cancer cells, potentially mediated through K ATP channels, and enhanced the antiproliferative impact of doxorubicin.

Epirubicin is as effective as doxorubicin for cancer treatment with less heart damage, but doesn't work on doxorubicin-resistant cancers.

The combination of gemcitabine and vinorelbine is effective and safe for treating elderly patients with advanced breast cancer previously treated with anthracyclines and taxanes.

This study found that ALRN-6924, a clinical-stage dual inhibitor, can selectively protect human scalp hair follicles from paclitaxel-induced toxicity and damage by inducing transient cell cycle arrest in healthy cells without affecting cancer cells, potentially reducing chemotherapy-induced alopecia.

In this study, blocking autophagy with 3-methyladenine significantly improved the survival of inner ear hair cells in a gentamicin-induced ototoxic mouse model.

In this study, lysocellin induced G1 phase arrest in human osteosarcoma cells, but diminished the cytotoxic efficacy of etoposide, while its derivative alopestatin may reduce etoposide-induced alopecia in a rat model.

In this Phase II study, BAY 43–9006, taken orally for renal cell carcinoma, stabilized disease in 30% of patients, with 40% responding positively, although the targets remain unclear.

The new chemotherapy combination for advanced lung cancer showed a 35.7% response rate but caused significant side effects.

This study found that DVd therapy is at least as effective as VAD/VAd for treating multiple myeloma and causes fewer side effects and reduced hospital visits.

This review describes the unique pharmacological profile and clinical applications of pegylated liposomal doxorubicin, emphasizing its role in Kaposi's sarcoma and recurrent ovarian cancer, but reports no new clinical results.